Canada Isn't on the Farm Team. We Just Haven't Studied the Playbook Yet.

Any team that's losing does the same thing first: it studies the competition. Not to feel bad about the scoreboard — to figure out exactly what the other team's gameplay is, so it can be matched and beaten. That's the exercise here. The US, UK, Israel, and Australia have spent decades building a specific set of tax incentives that make patient, risk-tolerant capital cheaper to hold in life sciences. Canada has real strengths — world-class science and high calibre research output, founders who keep building here despite the friction. What we haven't done yet is study the other team's playbook closely enough to run our own version of it.

There are five stages where that playbook shows up most clearly: getting a company its first real institutional cheque, keeping investors in the game after a loss instead of losing them for good, rewarding capital that stays through the hardest clinical rounds instead of only rewarding an early exit, fixing the one federal tool that was never built with clinical trials in mind, and closing the gap between what we fund to invent something and what we fund to actually sell it. Here's the gameplay at each stage — theirs, and the version Canada could be running.

1. Getting Started: The First Institutional Cheque

The hardest cheque for a Canadian life sciences startup is the first real institutional one — the one that turns a founder with grant money and a lab bench into a company with an actual investor on the cap table. Right now, Canada makes founders re-win that stage every year through grants instead of building the syndicate relationships that carry a company forward.

British Columbia already solved a version of this in its own backyard. Under the Small Business Venture Capital Act, an investor who puts equity into a registered venture capital corporation or eligible business corporation gets a 30% provincial tax credit — refundable for individuals, up to $300,000 per investor on investments of $1 million or more. It's been running since the early 2000s, and it exists for one reason: writing the first institutional cheque into an unproven company is the riskiest capital in the system, so BC decided to subsidize the risk instead of subsidizing the company.

The pattern shows up in what BC has actually built. The province punches well above its size in capital-efficient platform technologies — AbCellera, Xenon Pharmaceuticals, and Aspect Biosystems all spun out of UBC and grew into global players in antibody discovery, neuroscience, and bioprinting. That's not proof the tax credit built any one of them, but it fits a province that has spent two decades making it cheaper for local capital to take the first swing at an unproven idea.

Nothing like that exists federally. A Canadian life sciences startup's early runway is built almost entirely on public money instead: SR&ED tax credits, IRAP contributions, and now the federal government's own $150 million BDC Life Sciences Venture Fund and the new $1 billion Venture and Growth Capital Catalyst Initiative. Every one of those is a grant or a public fund writing the cheque directly. None of them make it cheaper for a private syndicate to write it instead.

That's the tell. Ottawa just built a $150 million public fund specifically because private institutional capital wasn't showing up early enough. A 30% federal credit modeled on BC's, applied to the first institutional equity cheque into an eligible Canadian startup, would fix the same gap from the other direction — by making it worth a private fund's while to be first in, instead of asking a Crown corporation to keep doing it alone.

A federal version would need to:

✅ Apply only to the first institutional round, not follow-on capital

✅ Match BC's split: refundable for individual investors, non-refundable for corporate ones

✅ Sit alongside SR&ED, not replace it — one funds the science, the other funds the ownership stake

Grants keep a company alive. Only an institutional cheque turns it into a company someone owns enough of to fight for.

2. Surviving Failure: Recycling Loss Instead of Retiring It

Up to 90% of biotech discoveries fail before reaching a patient. That's the nature of the business. But in Canada, failure doesn't just cost investors their money — it costs the ecosystem the next company too.

Here's the leak: when a Canadian life sciences startup goes under, whatever capital the investor has left doesn't go looking for the next scientific bet. It goes into GICs, real estate, big-box retail stocks — anywhere safe. That money exits the life sciences ecosystem permanently, right when the next generation of lab scientists needs it most. Compare that to Boston, where a trial fails and within weeks local investors have redeployed their remaining capital into a new biotech platform down the street. Same failure, completely different outcome — because the surrounding capital culture treats loss as information, not as an exit signal.

The existing tools don't fix this. Canada's Allowable Business Investment Loss (ABIL) lets an investor deduct 50% of a business investment loss against any income, not just capital gains — and unlike a normal capital loss, there's no cap on the size of it; the unused portion carries back three years or forward ten. The US takes the opposite trade: Section 1244 lets an investor write off up to 100% of a qualifying startup stock loss as an ordinary loss, but only up to $50,000 a year ($100,000 filing jointly) — above that cap, it reverts to a standard capital loss. So on a smaller loss, a US investor recovers more of it, faster. On a genuinely large loss, Canada's uncapped, carry-forward treatment actually holds up better. Neither is simply "better" — they're two different bets on how big the losses will be.

What neither country does is condition any of that relief on reinvestment. The closest thing that exists anywhere is the US's Section 1045 rollover, which lets an investor defer tax on a gain by reinvesting it into another qualifying startup within 60 days — but that rewards a win, not a loss. As far as I can find, no jurisdiction currently gives an investor a credit for taking a startup loss and getting right back in. That gap is the actual idea here, not something borrowed from elsewhere.

Call it the 𝗦𝘁𝗮𝗿𝘁𝘂𝗽 𝗟𝗼𝘀𝘀 𝗥𝗲𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗖𝗿𝗲𝗱𝗶𝘁: an accredited investor who takes a qualifying early-stage loss gets an added tax credit on top of existing loss treatment, conditional on deploying capital equivalent to at least 75% of the lost amount into another eligible Canadian startup within 18 months. Illustrative example: an investor loses $200,000 on a failed seed investment, claims the ABIL as usual, then reinvests $150,000 into a new Canadian startup within the window — the credit reduces their net cost of staying in the game, instead of just cushioning their exit from it.

A Canadian version would need to:

✅ 𝗠𝗼𝗺𝗲𝗻𝘁𝘂𝗺 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗱: Trigger only on a genuine qualifying early-stage loss, with at least 75% of the capital reinvested into another eligible Canadian startup within 18 months

✅ 𝗡𝗼 𝗿𝗲𝗰𝘆𝗰𝗹𝗶𝗻𝗴 𝗴𝗮𝗺𝗲𝘀: The credit can't be used to shuffle money between friends, family, or affiliated entities — it has to land in a genuinely independent company

✅ 𝗦𝗶𝘁 𝗼𝗻 𝘁𝗼𝗽 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗕𝗜𝗟, 𝗻𝗼𝘁 𝗿𝗲𝗽𝗹𝗮𝗰𝗲 𝗶𝘁: one absorbs the loss, the other funds the comeback

Ottawa's response to the scale-up gap has mostly been to write bigger cheques: new public funds, new subsidy programs. But every time a Canadian biotech goes bankrupt, our already-small pool of private life sciences investors shrinks a little more. We keep letting our most experienced healthcare investors walk away after a bad outcome — and then wonder why the next pipeline is starved for cash. This fix doesn't require new public money. It converts a private loss into private runway for the next company. Canada deserves more than being just good enough for the farm team.

3. Staying In: Taxing the Exit, Not the Hold

Almost all of Canada's life sciences companies follow the same trajectory: get through Phase I and sometimes Phase II, and then get sold. Not because of drug failures. Because there are no incentives in Canada's tax structure for investors to stay in past that point.

The US, UK, Israel, and Australia figured this out decades ago and built the fix into how capital gains get taxed. The US calls it Qualified Small Business Stock: hold eligible startup stock long enough and exclude up to 100% of federal capital gains tax on exit. The UK's EIS and SEIS exempt qualifying shares held three-plus years from capital gains entirely. Australia's Early Stage Innovation Company regime exempts gains on shares held one to ten years. Israel's Angels Law works through a tax credit and deferral instead, but the goal is the same: make it cheaper to be patient capital in an unproven company.

Canada's Lifetime Capital Gains Exemption solves a different problem. It shelters about $1.25 million for a founder selling shares in a private Canadian-controlled company. Real, and it helps. But it was never built to reward the investor writing the Series B or C cheque that carries a company through Phase 2 and 3 — and once a scale-up lists publicly to raise the capital that stage requires, the shares stop qualifying entirely. We built an exemption for the exit and left the risk-taking in between unrewarded.

Fusion Pharmaceuticals is a case study in real time. Built out of McMaster research in Hamilton on a $25 million Series A, it advanced its lead radioconjugate into Phase 2 and two more programs into Phase 1, then was acquired by AstraZeneca in 2024 for up to $2.4 billion. The Hamilton facility stays open — a real win. But the company that carried the risk through clinical proof needed a foreign strategic to fund the rest of the money, and the long-term ownership now sits with a Swedish multinational. That's export-and-buy-back in its clearest form: we keep the building, we lose the company.

A Canadian QSBS equivalent wouldn't have stopped that deal. What it would do is change the math for the domestic investor deciding whether to stay in for the next round instead of taking a strategic's offer at Phase 2 — because right now that investor pays full capital gains tax on a win either way, while their counterpart abroad does not.

Any Canadian version would need to:

✅ Target long-term holds in life sciences scale-ups, not any small business

✅ Survive a public listing, since that's often how a scale-up funds this exact stage

✅ Sit alongside the LCGE, not replace it — one rewards the exit, the other rewards staying through the hardest years

If Canadian capital is going to behave like an owner instead of a landlord chasing the first good offer, the tax code has to reward staying, not just selling.

4. The Sector-Specific Gap: Why SR&ED Doesn't Work for Clinical Trials

Canada's clinical trial market share dropped from 6% to 4% in four years. That's $2.5 billion in annual trial spending and 20,000 jobs that used to be ours. And we're losing that share in a global trials market that's growing to $82 billion, representing roughly 30% of the entire biopharma industry's R&D spend.

Here's the part most people miss: SR&ED — Scientific Research and Experimental Development, Canada's flagship R&D tax credit — wasn't built for this, and the mismatch is structural. SR&ED rewards companies for owning and commercializing R&D in Canada — the logic being that if you build it here, you'll also patent it, manufacture it, and sell it from here. That works cleanly for a tech company writing software or a forestry company developing a new process: do the R&D here, hold the IP here, capture the full value chain here.

Clinical trials don't work that way. When a multinational sponsor runs a Phase II trial in Toronto, Canada was never going to end up owning that drug's IP — it's already owned somewhere else. What Canada captures instead is the trial itself: the jobs, the sites, the patient data, the lab and manufacturing work tied to running it here. None of that requires Canadian ownership of the underlying science. But SR&ED still gates its refundable credit on Canadian-controlled private corporation (CCPC) status — testing for ownership, when the actual value Canada should be fighting for is activity. A foreign-backed sponsor deciding where to run a trial gets zero incentive from us, while Australia built its R&D tax credit around exactly this distinction and has been winning that business.

𝗧𝗵𝗲 𝗳𝗶𝘅: Extend refundable SR&ED offsets for Phase I–III trials to both CCPCs and foreign-backed entities trialing in Canada.

✅ Extend refundable SR&ED offsets to Phase I–III trials

✅ Include foreign-backed entities trialing in Canada, not just CCPCs

✅ Reward the activity happening here, not just the ownership sitting here

We built a tax tool for one kind of innovation and are trying to make it fit another. Time to fix the tool.

5. The Other Half of the Job: Funding Commercialization, Not Just Invention

Over the past decade, federal budgets have referenced "research and innovation" roughly 34 times more often than "commercialization." That number is a policy blind spot with a major price tag.

We've built an entire tax and grant architecture that rewards invention and almost nothing that rewards the harder, more expensive work of turning invention into revenue. That includes the dirty word "selling."

𝗧𝗵𝗲 𝗽𝗿𝗼𝗯𝗹𝗲𝗺 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝘀𝘁𝗮𝘁𝘂𝘀 𝗾𝘂𝗼: SR&ED will subsidize your lab work generously. It will not touch your first sales hire, your market development budget, or the channel-building that actually gets a product to a customer.

So founders get pushed to over-invest in invention relative to go-to-market — not because that's the better business decision, but because it's the only one with a tax credit attached to it. This shows up in how companies build: research gets funded, so research gets built. Go-to-market doesn't, so it gets under-resourced, delayed, or skipped until a foreign acquirer shows up with both the capital and the commercial infrastructure Canada never subsidized.

𝗧𝗵𝗲 𝗳𝗶𝘅: A "Commercialization Matching Credit" — a matching investment credit for commercialization spend, sales hires, market development, and channel building, calibrated against existing R&D incentives so the two aren't competing for the same founder's limited runway.

Two design details matter as much as the credit itself. Eligibility has to be based on the underlying commercialization activity itself — not company size, sector, or ownership structure — to keep this compliant with Canada's WTO obligations under the Agreement on Subsidies and Countervailing Measures. And it has to be tied to independently verifiable outcomes: net-new customer contracts, documented market entry, revenue growth in a new segment. Not self-reported activity. SR&ED has spent years fighting verification weaknesses that turned a research incentive into a compliance minefield — we shouldn't build its successor with the same flaw.

✅ Match commercialization spend the way SR&ED matches R&D spend

✅ Tie eligibility to verifiable commercial outcomes, not self-attestation

✅ Design for WTO compliance from day one, not as an afterthought

Show me the incentive, and I'll show you the outcome. Right now, ours only rewards half the job.

Five Plays, One Gameplan

Read individually, each of these looks like a narrow technical ask. Read together, they're a gameplan the competition has already run successfully: get the first institutional cheque flowing, keep investors in the game after a loss instead of losing them for good, reward the capital that stays through the hardest clinical rounds instead of only rewarding an early exit, stop excluding the sponsors who actually decide where trial activity lands, and fund the sale as seriously as we fund the science. Run all five, and Canadian capital starts playing to win the game, not just to survive long enough to get bought by someone who studied the playbook first.